http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112336872-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112336872-B |
| titleOfInvention | Nano-aptamer for multi-specific antibody delivery and application and construction method thereof |
| abstract | The invention relates to a nano aptamer for multi-specific antibody delivery and an application and a construction method thereof. The nano aptamer is formed by connecting a nano carrier with an anti-Fc segment antibody or an anti-Fc segment antibody fragment part through a chemical bond; wherein the Fab domain of the anti-Fc fragment antibody or anti-Fc fragment antibody is capable of non-covalent binding to the Fc domain of the specific antibody delivered; the specific antibody delivered is of the same generic origin as the Fc fragment recognized by the anti-Fc fragment antibody or anti-Fc fragment antibody fragment. The nano-aptamer can be rapidly, efficiently and controllably combined with various types of antibodies, so that the multivalence and the multispecific performance of the antibodies are realized. The invention creatively applies the constructed nano antibody delivery platform to the preparation of immunotherapy drugs or treatment drugs for tumors or autoimmune diseases for the first time, and can obviously improve the immunotherapy effect. |
| priorityDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.